Stock prices for embryonic stem cell research companies took a hit when the U.S. Senate failed to pass a bill to overturn President Bush’s stem cell funding policy by a veto proof margin. Worcester, MA’s, Advanced Cell Technology—which opened an office in California to try and take advantage of the cornicopia of Proposition 71 money—lost value, as did California’s Geron. Some adult stem cell companies also lost ground, but others gained.
Well, the market doesn’t lie: A big part of the drive to overturn Bush’s policy is pure corporate welfare pork. Sooweeee!
YOU MIGHT ALSO LIKE
Undercover in Canada’s Lawless Abortion Industry
On November 27, 2023, thirty-six-year-old Alissa Golob walked through the doors of the Cabbagetown Women’s Clinic in…
The Return of Blasphemy Laws?
Over my many years in the U.S., I have resisted the temptation to buy into the catastrophism…
The Fourth Watch
The following is an excerpt from the first edition of The Fourth Watch, a newsletter about Catholicism from First…
